Completed OBSERVATIONAL NCT06152393

Value of an Intrathecal Synthesis Index of Specific Antitreponema IgG for Neurosyphilis Diagnosis

Retro-prospective Multicentric Study Aiming to Evaluate the Benefit of Measuring an Intrathecal Synthesis Index of Specific Antitreponema IgG for Patients Suspected of Neurosyphilis

Sponsor: Swiss HIV Cohort Study

Conditions Neurosyphilis

Interventions Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.

Updated 3 times since 2023 Last updated: Nov 21, 2023 Started: Mar 1, 2019 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06152393, this observational or N/A phase trial focuses on Neurosyphilis and remains completed. Sponsored by Swiss HIV Cohort Study, it has been updated 3 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2023 — Jul 2024 [monthly]

Completed

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss HIV Cohort Study
Swiss National Science Foundation
University Hospital, Geneva

Data source: University Hospital, Geneva

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland